Business
GE HealthCare unveils Revolution™ Vibe CT system with Unlimited One-Beat Cardiac imaging and AI Solutions
GE HealthCare’s Revolution Vibe CTi enables more facilities to elevate patient care by offering advanced cardiac imaging technology that helps deliver fast,
About this update from Ge Healthcare Technologies Inc.
[{"type":"text","content":"\n\nGE HealthCare’s Revolution Vibe CTi enables more facilities to elevate patient care by offering advanced cardiac imaging technology that helps deliver fast, accurate diagnoses, improve operational efficiency, and enhance patient outcomes.\n\n\nCardiovascular disease (CVD) is the leading cause of death and healthcare costs worldwide,ii with research projecting it could cause over 23 million deaths by 2030.iii The average number of cardiac computed tomography (CT) procedures performed per site is expected to increase 175 percent,iv highlighting its value as a first-line imaging tool for diagnosis, treatment planning, and post-treatment follow-up.\n\n\n CHICAGO--(BUSINESS WIRE)--\nAt the American College of Cardiology 2025 meeting, GE HealthCare (Nasdaq: GEHC) will proudly introduce Revolution™ Vibe,i a new computed tomography (CT) system with Unlimited One-Beat Cardiac imaging to deliver consistent, high-quality images for patients, even in challenging cases like atrial fibrillation and heavily calcified coronaries. Combined with the company’s impressive ECG-less Cardiac, TrueFidelity DL, SnapShot Freeze 2, and Effortless Workflow's AI-powered solutions, Revolution Vibe enables fast, accurate diagnoses, a more comfortable patient experience, and more efficient workflows.v\n\nAs cardiovascular disease (CVD) continues to rise globally,vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. CCTA offers a non-invasive, cost-effective, and highly sensitive method for diagnosing coronary artery disease (CAD), making it a valuable tool for clinicians. The National Institute for Health and Care Excellence (NICE) recommends CCTA as the first-line investigation for patients with chest pain due to suspected CAD, highlighting its importance in improving diagnostic certainty. vii Similarly, recent increases in Medicare reimbursement rates for CCTA are a positive step towards making this technology more accessible.\n\n\"Expanding access to CCTA is crucial for managing the rising prevalence of CVD, ensuring timely and accurate diagnoses for a larger patient population,” shares Jean-Luc Procaccini, President and CEO, Molecular Imaging and Computed Tomography, GE HealthCare. “Our introduction of Revolution Vibe underscores our commitment to this mission. The system is designed to encou...